Xu Zhang

机构：Nankai University, Chinese PLA General Hospital · ORCID：0000-0003-4283-409X

发表论文 46 篇 · 总被引 607 次 · h-index 15

代表论文

• Deep learning algorithm-based multimodal MRI radiomics and pathomics data improve prediction of bone metastases in primary prostate cancer (2024 · Journal of Cancer Research and Clinical Oncology · 被引 56)
• Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy (2021 · European Urology · 被引 37)
• SPI1 is a prognostic biomarker of immune infiltration and immunotherapy efficacy in clear cell renal cell carcinoma (2022 · Discover Oncology · 被引 19)
• Loss of cell division cycle‑associated 5 promotes cell apoptosis by activating DNA damage response in clear cell renal cell carcinoma (2022 · International Journal of Oncology · 被引 18)
• CD146 as a Prognostic-Related Biomarker in ccRCC Correlating With Immune Infiltrates (2021 · Frontiers in Oncology · 被引 16)
• The efficacy and safety of addition of pegylated interferon to long-term nucleos(t)ide analogue therapy on functional cure of chronic hepatitis B patient: a systematic review and meta-analysis (2024 · Frontiers in Pharmacology · 被引 11)